Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

14.36 -0.65 (-4.33%)
Streaming Delayed Price Updated: 10:34 AM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 140,725
Open 14.70
Bid (Size) 14.33 (2)
Ask (Size) 14.37 (6)
Prev. Close 15.01
Today's Range 14.10 - 14.73
52wk Range 11.91 - 27.96
Shares Outstanding 157,168,321
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Iovance Biotherapeutics Just Flashed A Bullish Sign Despite Melanoma Drug Delay
This biotech stock is mounting a two-day recovery and is well above its 50-day line. 
Via Investor's Business Daily
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga

Performance

YTD
-24.69%
-24.69%
1 Month
-14.93%
-14.93%
3 Month
-7.41%
-7.41%
6 Month
-22.60%
-22.60%
1 Year
-19.19%
-19.19%

More News

Read More
Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy
Via Benzinga
All The Stocks That Moved Wednesday From CNBC's 'Fast Money: Halftime Report'
Via Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recap: Iovance Biotherapeutics Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers
Via Benzinga
70 Biggest Movers From Friday
Via Benzinga
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
Why Iovance Is Up Nearly 11% Today
Via The Motley Fool
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll
Via Benzinga
Why Iovance Biotherapeutics Soared 40% In June
Via The Motley Fool
June’s Best and Worst Performing Russell 1,000 Stocks
Via Talk Markets
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.